National registry for IgG4-related disease in China
Part of Immune system & allergy clinical trials.
This study is a registry that collects information about people diagnosed with IgG4-related disease (a specific immune-related condition). It helps doctors better understand the condition and how it looks and behaves in real life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must meet the study’s diagnosis standards for IgG4-related disease.
- Your diagnosis should not be something else that can look similar to IgG4-related disease.
- If your symptoms could be caused by a tumor, you likely would not qualify.
- If your symptoms are due to vasculitis (blood vessel inflammation), you likely would not qualify.
- If your symptoms are due to sarcoidosis (another inflammatory condition), you likely would not qualify.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is a study that follows people diagnosed with IgG4-related disease to better understand the condition. It may help researchers confirm diagnoses and learn how the disease affects different organs over time.
This trial tests a short course of steroids combined with mycophenolate mofetil (MMF) for people with active IgG4-related disease who have not been treated before or whose disease came back after stopping treatment. The goal is to see if this combination helps control the disease better.
This trial tests whether a special type of immune cell therapy (CAR-T) can help people whose IgG4-related disease persists despite steroids or rituximab. It focuses on those with inflammation in two or more major organs.
This study tests a drug called lenalidomide to see if it can help control active IgG4-related disease, a condition that causes inflammation and swelling in organs. The drug is taken by mouth, and the study compares it to a placebo (a pill with no medicine).
This trial tests a new drug called ACE1831 for people with active IgG4-related disease that affects more than one organ. It aims to see if the drug can safely control the disease and reduce the need for steroids.
This trial tests a new medicine called IMM0306 for IgG4-related disease, a condition where the immune system attacks multiple organs in your body. The study aims to see if IMM0306 can help control your disease and reduce flare-ups while using less steroid medication.
Hear when a new IgG4-Related Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.